Overview

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

Status:
Completed

Trial end date:
2019-09-19

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Antiparkinson Agents
Carbidopa
Carbidopa, levodopa drug combination
Levodopa